1887

Chapter 109 : Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH109-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH109-2.gif

Abstract:

Malignancies of the immune system are primarily represented by the malignant lymphomas and a smaller number of nonlymphoid neoplasms that originate from cells involved in antigen presentation and processing. The diagnosis and classification of these tumors have benefited enormously from advances in cellular and molecular immunology, as well as from careful dissection of the molecular genetics of the cancers themselves. Our ability to correctly diagnose tumors of the immune system, which in many instances show little morphological variation, requires the careful application of both immunologic tumor markers as well as molecular (DNA- or RNA-based) tumor markers. Therefore, malignancies of the immune system are not only interesting models of normal immune cells but are also excellent examples of the variety of molecular and immunological approaches for assessing cancers.

Citation: Jaffe E, Raffeld M. 2016. Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics, p 1015-1035. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch109
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Schematic diagram showing stages of T-cell differentiation. Neoplasms can be related to precursor and mature or peripheral T lymphocytes. Antigenic phenotype correlates with maturational stage. Note that CD7 is the earliest T-associated antigen.

Citation: Jaffe E, Raffeld M. 2016. Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics, p 1015-1035. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch109
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Schematic diagram showing stages of B-cell differentiation. Lymphomas can be related to precursor B-cell, mature B-cell, and secretory B-cell (plasma cell) stages of differentiation. Note that CD79a has the broadest range of reactivity, staining precursor, mature, and secretory B cells.

Citation: Jaffe E, Raffeld M. 2016. Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics, p 1015-1035. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch109
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch109
1. Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfeld A, van Unnik J. 1974. Letter: Classification of non-Hodgkin's lymphomas. Lancet 2:405408.
2. Lukes RJ, Collins RD. 1974. Immunologic characterization of human malignant lymphomas. Cancer 34(Suppl):14881503.[PubMed].[CrossRef]
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:13611392.[PubMed]
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW,. 2008. In Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H (ed), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. International Agency for Research on Cancer, Lyon, France.
5. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. 2011. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:50195032.[CrossRef].[PubMed]
6. Rabbitts TH, van Straaten P, Rabbitts PH, Watson J. 1985. Discussion on the metabolism of c-myc mRNA and protein. Proc R Soc Lond B Biol Sci 226:7982.[PubMed].[CrossRef]
7. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. 1991. Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:48464853.[PubMed].[CrossRef]
8. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM. 1985. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315:340343.[PubMed].[CrossRef]
9. Calvo KR, McCoy CS, Stetler-Stevenson M. 2011. Flow cytometry immunophenotyping of hematolymphoid neoplasia. Methods Mol Biol 699:295316.[CrossRef].[PubMed]
10. Mason DY, Cordell JL, Brown MH, Borst J, Jones M, Pulford K, Jaffe E, Ralfkiaer E, Dallenbach F, Stein H, Pileri S, Gatter KC. 1995. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 86:14531459.[PubMed]
11. Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. 1995. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA 92:93489352.[PubMed].[CrossRef]
12. Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP. 2005. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 124:295302.[CrossRef].[PubMed]
13. Shi SR, Cote RJ, Taylor CR. 1997. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 45:327343.[PubMed].[CrossRef]
14. Krenacs L, Krenacs T, Raffeld M. 1999. Antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. Methods Mol Biol 115:8593.[CrossRef].[PubMed]
15. van Dongen JJ, Wolvers-Tettero IL. 1991. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 198:93174.[PubMed].[CrossRef]
16. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. 2003. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:22572317.[CrossRef].[PubMed]
17. Diaz-Cano SJ, Blanes A, Wolfe HJ. 2001. PCR techniques for clonality assays. Diagn Mol Pathol 10:2433.[PubMed].[CrossRef]
18. Nurse GT, Jenkins T. 1973. G.-6-P.D. phenotypes and X-chromosome inactivation. Lancet 1:99100.[PubMed].[CrossRef]
19. Robertson KD, Jones PA. 1999. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18:38103820.[CrossRef].[PubMed]
20. Kopp P, Jaggi R, Tobler A, Borisch B, Oestreicher M, Sabacan L, Jameson JL, Fey MF. 1997. Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue. Mol Cell Probes 11:217228.[CrossRef].[PubMed]
21. Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. 2013. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 37:323332.[CrossRef].[PubMed]
22. Barth TF, Floßbach L, Bernd HW, Bob R, Buck M, Cogliatti SB, Feller AC, Hansmann ML, Hartmann S, Horn H, Klapper W, Kradolfer D, Mattfeldt T, Möller P, Rosenwald A, Stein H, Thorns C, Ott G. 2012. Round robin test for detection of genomic aberrations in non-Hodgkin lymphoma by in situ hybridization. Pathologe 34:329334. (In German.)
23. Kluin PH, Schuuring E. 1997. FISH and related techniques in the diagnosis of lymphoma. Cancer Surv 30:320.[PubMed]
24. Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HR. 2005. Basic principles of real-time quantitative PCR. Expert Rev Mol Diagn 5:209219.[CrossRef].[PubMed]
25. Kingma DW, Medeiros LJ, Barletta J, Raffeld M, Mann RB, Ambinder RF, Jaffe ES. 1994. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease. Am J Surg Pathol 18:4861.[PubMed].[CrossRef]
26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM Lymphoma/Leukemia Molecular Profiling Project. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:19371947.[CrossRef].[PubMed]
27. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. 2014. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:29152923.[CrossRef].[PubMed]
28. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. 2003. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:49444951.[CrossRef].[PubMed]
29. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM. 2014. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:12141217.[CrossRef].[PubMed]
30. Pittaluga S, Uppenkamp M, Cossman J. 1987. Development of T3/T cell receptor gene expression in human pre-T neoplasms. Blood 69:10621067.[PubMed]
31. Szczepan´ski T, Langerak AW, Willemse MJ, Wolvers-Tettero IL, van Wering ER, van Dongen JJ. 2000. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect ‘end-stage’ recombinations: implications for minimal residual disease monitoring. Leukemia 14:12081214.[PubMed].[CrossRef]
32. Szczepanński T, Pongers-Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER, van Dongen JJ. 1999. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant Dh6-19 and Dh7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor αβ lineage. Blood 93:40794085.[PubMed]
33. Buccheri V, Mihaljevi c´ B, Matutes E, Dyer MJ, Mason DY, Catovsky D. 1993. mb-1: a new marker for B-lineage lymphoblastic leukemia. Blood 82:853857.[PubMed]
34. Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldmann TA. 1983. Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest 71:301313.[PubMed].[CrossRef]
35. Szczepan´ski T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ. 2001. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 15:14151423.[PubMed].[CrossRef]
36. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, Shad AT, Lage JM, Magrath IT, Azumi N, Harris NL, Cossman J, Jaffe ES. 1998. Precursor B-lymphoblastic lymphoma presenting as a solitary bone tumor and mimicking Ewing's sarcoma: a report of four cases and review of the literature. Am J Surg Pathol 22:795804.[PubMed].[CrossRef]
37. Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL. 1996. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:3137.[PubMed].[CrossRef]
38. Kumar S, Green GA, Teruya-Feldstein J, Raffeld M, Jaffe ES. 1996. Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. Mod Pathol 9:925929.[PubMed]
39. Jaffe ES, Raffeld M, Medeiros LJ. 1993. Histopathologic subtypes of indolent lymphomas: caricatures of the mature B-cell system. Semin Oncol 20(Suppl 5):330.[PubMed]
40. Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J, Mason DY. 1992. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140:10891095.[PubMed]
41. Horsman DE, Gascoyne RD, Coupland RW, Coldman AJ, Adomat SA. 1995. Comparison of cytogenetic analysis, Southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol 103:472478.[PubMed].[CrossRef]
42. Medeiros LJ, Van Krieken JH, Jaffe ES, Raffeld M. 1990. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 76:20862090.[PubMed]
43. Raffeld M, Jaffe ES. 1991. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78:259263.[PubMed]
44. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Müller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC Lymphoma/Leukemia Molecular Profiling Project. 2005. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106:43154321.[CrossRef].[PubMed]
45. Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, Song JY, Woroniecka R, Rymkiewicz G, Klapper W, Hartmann EM, Sujobert P, Wlodarska I, Ferry JA, Gaulard P, Ott G, Rosenwald A, Lopez-Guillermo A, Quintanilla-Martinez L, Harris NL, Jaffe ES, Siebert R, Campo E, Beà S. 2013. CCND2 rearrangements are the most frequent genetic events in cyclin D1 mantle cell lymphoma. Blood 121:13941402.[CrossRef].[PubMed]
46. Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH. 2001. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47:195201.[PubMed]
47. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. 2003. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100:99919996.[CrossRef].[PubMed]
48. Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C. 2000. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 156:14331439.[CrossRef].[PubMed]
49. Wotherspoon AC, Finn TM, Isaacson PG. 1995. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 85:20002004.[PubMed]
50. Schaffner C, Stilgenbauer S, Rappold GA, Döhner H, Lichter P. 1999. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94:748753.[PubMed]
51. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:1552415529.[CrossRef].[PubMed]
52. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:29993004.[CrossRef].[PubMed]
53. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:1394413949.[CrossRef].[PubMed]
54. Tobin G, Rosenquist R. 2005. Prognostic usage of VH gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol 22:217228.[CrossRef].[PubMed]
55. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. 2001. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:16391647.[PubMed].[CrossRef]
56. Wiggers TG, Westra G, Westers TM, Abbes AP, Strunk A, Kuiper-Kramer E, Poddighe P, van de Loosdrecht AA, Chamuleau ME. 2014. ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status. Cytometry B Clin Cytom 86:280287.[CrossRef].[PubMed]
57. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR. 2012. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367:826833.[CrossRef].[PubMed]
58. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP. 2013. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121:20512058.[CrossRef].[PubMed]
59. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. 2005. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296303.[CrossRef].[PubMed]
60. Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E, Kindl S, Rosso R, Astori C, Buonanno MC. 1993. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 11:23062313.[PubMed]
61. Lamarre L, Jacobson JO, Aisenberg AC, Harris NL. 1989. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol 13:730739.[PubMed].[CrossRef]
62. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MA, Posnett DN, Knowles DM, Asch AS. 1996. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med 183:23852390.[PubMed].[CrossRef]
63. DiGiuseppe JA, Nelson WG, Seifter EJ, Boitnott JK, Mann RB. 1994. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 12:25732579.[PubMed]
64. Fang JM, Finn WG, Hussong JW, Goolsby CL, Cubbon AR, Variakojis D. 1999. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol 12:295300.[PubMed]
65. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M. 1993. p53 mutation is associated with progression in follicular lymphomas. Blood 82:19942004.[PubMed]
66. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M. 1997. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601609.[PubMed]
67. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503511.[CrossRef].[PubMed]
68. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA. 2003. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:38713879.[CrossRef].[PubMed]
69. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851862.[CrossRef].[PubMed]
70. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275282.[CrossRef].[PubMed]
71. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. 2011. Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115119.[CrossRef].[PubMed]
72. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. 2010. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:8892.[CrossRef].[PubMed]
73. Yang Y, Shaffer AL III, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM. 2012. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723737.[CrossRef].[PubMed]
74. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M, Cassiman JJ, De Wolf-Peeters C. 1992. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 16:3748.[PubMed].[CrossRef]
75. Otsuki T, Kumar S, Ensoli B, Kingma DW, Yano T, Stetler-Stevenson M, Jaffe ES, Raffeld M. 1996. Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. Leukemia 10:13581362.[PubMed]
76. Boerma EG, Siebert R, Kluin PM, Baudis M. 2009. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 23:225234.[CrossRef].[PubMed]
77. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD. 2012. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:34523459.[CrossRef].[PubMed]
78. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB. 2012. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:34603467.[CrossRef].[PubMed]
79. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM Lymphoma/Leukemia Molecular Profiling Project. 2006. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:24312442.
80. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trümper L, Stein H, Siebert R Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. 2006. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:24192430.[CrossRef].[PubMed]
81. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM. 2011. Double-hit B-cell lymphomas. Blood 117:23192331.[CrossRef].[PubMed]
82. Jaffe ES, Pittaluga S. 2011. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program 2011:506514.[CrossRef].[PubMed]
83. zur Stadt U, Hoser G, Reiter A, Welte K, Sykora KW. 1997. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. Ann Oncol 8(Suppl 1):3135.[PubMed]
84. Jaffe ES, Krenacs L, Raffeld M. 1997. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol 8(Suppl 2):1724.[PubMed]
85. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. 1987. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Pathol 128:181201.[PubMed]
86. Frizzera G, Kaneko Y, Sakurai M. 1989. Angioimmunoblastic lymphadenopathy and related disorders: a retrospective look in search of definitions. Leukemia 3:15.[PubMed]
87. Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, Dogan A. 2002. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627633.[PubMed].[CrossRef]
88. Grogg KL, Macon WR, Kurtin PJ, Nascimento AG, Lae ME, Ahmed I. 2005. A survey of clusterin and fascin expression in sarcomas and spindle cell neoplasms: strong clusterin immunostaining is highly specific for follicular dendritic cell tumor. Mod Pathol 18:260266.[CrossRef].[PubMed]
89. Dunleavy K, Wilson WH, Jaffe ES. 2007. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol 14:348353.[CrossRef].[PubMed]
90. Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. 1992. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 79:17891795.[PubMed]
91. Abruzzo LV, Schmidt K, Weiss LM, Jaffe ES, Medeiros LJ, Sander CA, Raffeld M. 1993. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood 82:241246.[PubMed]
92. Quintanilla-Martinez L, Fend F, Moguel LR, Spilove L, Beaty MW, Kingma DW, Raffeld M, Jaffe ES. 1999. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol 23:12331240.[PubMed].[CrossRef]
93. Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M, Jaffe ES. 2013. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol 37:816826.[CrossRef].[PubMed]
94. Jaffe ES, Nicolae A, Pittaluga S. 2013. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol 26(Suppl 1):S71S87.[CrossRef].[PubMed]
95. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC International Peripheral T-Cell Lymphoma Project. 2010. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115:10261036.[CrossRef].[PubMed]
96. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P. 2007. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:49524963.[CrossRef].[PubMed]
97. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S. 2014. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171175.[CrossRef].[PubMed]
98. Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA. 2014. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166170.[CrossRef].[PubMed]
99. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM. 2013. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123:12931296.[CrossRef].[PubMed]
100. Bunn PA Jr, Schechter GP, Jaffe E, Blayney D, Young RC, Matthews MJ, Blattner W, Broder S, Robert-Guroff M, Gallo RC. 1983. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 309:257264.[CrossRef].[PubMed]
101. Hatta Y, Yamada Y, Tomonaga M, Miyoshi I, Said JW, Koeffler HP. 1999. Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia. Blood 93:613616.[PubMed]
102. Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M. 1999. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 111(Suppl 1):S46S55.[PubMed]
103. Spits H, Blom B, Jaleco AC, Weijer K, Verschuren MC, van Dongen JJ, Heemskerk MH, Res PC. 1998. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev 165:7586.[PubMed].[CrossRef]
104. de Bruin PC, Kummer JA, van der Valk P, van Heerde P, Kluin PM, Willemze R, Ossenkoppele GJ, Radaszkiewicz T, Meijer CJ. 1994. Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood 84:37853791.[PubMed]
105. Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC. 1996. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103111.[PubMed].[CrossRef]